Ray Therapeutics Inc.’s upsized and oversubscribed $100 million series A financing will support the firm’s ongoing efforts with optogenetics, an approach that deploys adeno-associated virus (AAV) gene therapy to deliver a light-sensitive, highly bioengineered protein found in nature to retinal cells.
Azura Ophthalmics Ltd. has divulged codrugs consisting of an immunomodulator moiety and a keratolytic agent reported to be useful for the treatment of eye and dermatological disorders.
Researchers from Senelix Co. Ltd. described the preclinical characterization of the novel adiponectin receptor protein 1/2 (ADIPOR1/2) agonist SL-100, which is being developed for the treatment of dry eye disease (DED).
A study comprising a total of 406 subjects, including both healthy individuals (n=54) and patients with dry eye (DE) disease was performed with the aim of discovering basal tear cytokine markers for disease diagnosis and severity. Based on guidelines, patients with DE were classified as predisposed DE (pDE, n=136), mild-moderate DE (mDE, n=185), and severe DE (sDE, n=31).
The SLC6A6 gene encodes the transporter of the amino acid taurine. In recently presented work, researchers from the Institute of Molecular and Clinical Ophthalmology Basel, University of Basel and affiliated organizations aimed to investigate the molecular pathology of a novel mutation in SLC6A6 and its association with a syndromic form of Leber congenital amaurosis (LCA).
Researchers from Augusta University recently presented data from a study that aimed to assess the role of acetyl-CoA acetyltransferase (ACAT1) in neurovascular damage during diabetic retinopathy (DR).
RSS
